Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?

BYDUREON™ (exenatide extended-release for injectable suspension). Highlights of prescribing information. 2012 Amylin Pharmaceuticals, Inc. Available from: https://www.accessdata.fda.gov/drugsatfda.../022200s000lbl.pdf.Search in Google Scholar

BYDUREON® (exenatide extended-release) for injectable suspension. Highlights of prescribing information. Astra-Zeneca Pharmaceuticals LP, revised April 2018. Available from: https://www.azpicentral.com/bydureon/pi_bydureon.pdf.Search in Google Scholar

Diabetes Fact Sheath, WHO, November 2008. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/.Search in Google Scholar

Frias JP, Nakhle S, Ruggles JA, Zhuplatov S, Klein E, Zhou R, Strange P. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 19, 40–48, 2017.10.1111/dom.12763Search in Google Scholar

Global Report on Diabetes, WHO, 2016. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.Search in Google Scholar

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359, 1577–1589, 2008.10.1056/NEJMoa0806470Search in Google Scholar

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149, 2015.10.2337/dc14-2441Search in Google Scholar

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3, e442, 2006.10.1371/journal.pmed.0030442Search in Google Scholar

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30, 239–245, 1981.10.1038/clpt.1981.1547249508Open DOISearch in Google Scholar

Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 46, 1179–1187, 2006.10.1177/009127000629162216988207Open DOISearch in Google Scholar

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405–412, 2000.10.1136/bmj.321.7258.405Search in Google Scholar

Syed YY, McCormack PL: Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. Drugs 75, 1141–1152, 2015.10.1007/s40265-015-0420-zSearch in Google Scholar

The use of the WHO-UMC system for standardized case causality assessment. World Health Organization (WHO) – Uppsala Monitoring Centre. Available from: http://www.who-umc.org/Graphics/24734.pdf.Search in Google Scholar

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853, 1998.10.1016/S0140-6736(98)07019-6Search in Google Scholar